Warning: The NCBI web site requires JavaScript to function. more...
The balance of Polo-like kinase 1 in tumorigenesis.
Lu LY, Yu X.
Cell Div. 2009 Jan 22;4:4.
Related citations
Cell type-- dependent effects of Polo-like kinase 1 inhibition compared with targeted polo box interference in cancer cell lines.
Fink J, Sanders K, Rippl A, Finkernagel S, Beckers TL, Schmidt M.
Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3189-97.
Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers.
Takahashi T, Sano B, Nagata T, Kato H, Sugiyama Y, Kunieda K, Kimura M, Okano Y, Saji S.
Cancer Sci. 2003 Feb;94(2):148-52.
Silencing of polo-like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: implications for the treatment of prostate cancer.
Reagan-Shaw S, Ahmad N.
FASEB J. 2005 Apr;19(6):611-3. Epub 2005 Jan 20.
Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo.
Spänkuch B, Heim S, Kurunci-Csacsko E, Lindenau C, Yuan J, Kaufmann M, Strebhardt K.
Cancer Res. 2006 Jun 1;66(11):5836-46.
Getting in and out of mitosis with Polo-like kinase-1.
van Vugt MA, Medema RH.
Oncogene. 2005 Apr 18;24(17):2844-59. Review.
Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells.
Spänkuch-Schmitt B, Wolf G, Solbach C, Loibl S, Knecht R, Stegmüller M, von Minckwitz G, Kaufmann M, Strebhardt K.
Oncogene. 2002 May 9;21(20):3162-71.
Polo box domain of Plk3 functions as a centrosome localization signal, overexpression of which causes mitotic arrest, cytokinesis defects, and apoptosis.
Jiang N, Wang X, Jhanwar-Uniyal M, Darzynkiewicz Z, Dai W.
J Biol Chem. 2006 Apr 14;281(15):10577-82. Epub 2006 Feb 14.
The natural product Aristolactam AIIIa as a new ligand targeting the polo-box domain of polo-like kinase 1 potently inhibits cancer cell proliferation.
Li L, Wang X, Chen J, Ding H, Zhang Y, Hu TC, Hu LH, Jiang HL, Shen X.
Acta Pharmacol Sin. 2009 Oct;30(10):1443-53.
Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis.
Gilmartin AG, Bleam MR, Richter MC, Erskine SG, Kruger RG, Madden L, Hassler DF, Smith GK, Gontarek RR, Courtney MP, Sutton D, Diamond MA, Jackson JR, Laquerre SG.
Cancer Res. 2009 Sep 1;69(17):6969-77. Epub 2009 Aug 18.
Overexpression of polo-like kinase 1 (PLK1) and chromosomal instability in bladder cancer.
Yamamoto Y, Matsuyama H, Kawauchi S, Matsumoto H, Nagao K, Ohmi C, Sakano S, Furuya T, Oga A, Naito K, Sasaki K.
Oncology. 2006;70(3):231-7. Epub 2006 Jul 6.
On the regulation and function of human polo-like kinase 1 (PLK1): effects of overexpression on cell cycle progression.
Mundt KE, Golsteyn RM, Lane HA, Nigg EA.
Biochem Biophys Res Commun. 1997 Oct 20;239(2):377-85.
Molecular interactions of Polo-like-kinase 1 with the mitotic kinesin-like protein CHO1/MKLP-1.
Liu X, Zhou T, Kuriyama R, Erikson RL.
J Cell Sci. 2004 Jul 1;117(Pt 15):3233-46. Epub 2004 Jun 15.
Cell division cycle 6, a mitotic substrate of polo-like kinase 1, regulates chromosomal segregation mediated by cyclin-dependent kinase 1 and separase.
Yim H, Erikson RL.
Proc Natl Acad Sci U S A. 2010 Nov 16;107(46):19742-7. Epub 2010 Nov 1.
Polo-like kinase 1 depletion induces DNA damage in early S prior to caspase activation.
Mol Cell Biol. 2009 May;29(10):2609-21. Epub 2009 Mar 16.
Functional independency between catalytic activity and subcellular targeting of polo-like kinase-1: phenotypes of ectopic overexpression of various mutants.
Ji JH, Jang YJ.
Cell Cycle. 2008 Jun 1;7(11):1597-603. Epub 2008 Mar 2.
Targeting polo-like kinase 1 for cancer therapy.
Strebhardt K, Ullrich A.
Nat Rev Cancer. 2006 Apr;6(4):321-30. Review.
Induction of antitumor immunity using dendritic cells electroporated with Polo-like kinase 1 (Plk1) mRNA in murine tumor models.
Park JS, Sohn HJ, Park GS, Chung YJ, Kim TG.
Cancer Sci. 2011 Aug;102(8):1448-54. doi: 10.1111/j.1349-7006.2011.01974.x. Epub 2011 Jun 23.
A case study from the chemistry core of the Pittsburgh Molecular Library Screening Center: the Polo-like kinase polo-box domain (Plk1-PBD).
Wipf P, Arnold D, Carter K, Dong S, Johnston PA, Sharlow E, Lazo JS, Huryn D.
Curr Top Med Chem. 2009;9(13):1194-205. Review.
A high-throughput assay based on fluorescence polarization for inhibitors of the polo-box domain of polo-like kinase 1.
Reindl W, Strebhardt K, Berg T.
Anal Biochem. 2008 Dec 15;383(2):205-9. Epub 2008 Aug 22.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on